Inflammation is a primary driver behind many fatal and life-threatening diseases. By targeting inflammation, Abcentra hopes to alleviate symptoms and treat underlying disease, creating a fuller life for patients.
Atherosclerosis occurs when substances such as fats, cholesterol, and immune cells build up on a patient’s artery walls, restricting blood flow to vital organs and tissues. In rheumatological patients, atherosclerosis is accelerated due to chronic inflammation, leading to a higher risk of heart attack. There is currently no therapy approved to prevent atherosclerotic progression in such patients, however studies demonstrate that an anti-inflammatory approach can prevent plaque progression.
Plaque psoriasis is a chronic inflammatory skin disease that affects 3 percent of the population and is associated with serious commodities such as cancer, diabetes and heart disease. Linked to overactive immune cells in the skin, psoriasis can be treated with immunomodulating therapies that reduce inflammation. These therapies can have serious side effects, however. There is a need for more targeted treatment options with minimal side effects.
Aortic Valve Stenosis
Aortic valve stenosis is the narrowing of the exit to the left ventricle of the heart such that problems result. Symptoms include angina, syncope and congestive heart failure. It is the most common form of valve disease, affecting more than one million patients in North America each year. Approximately 14 percent of cases are due to elevated Lp(a), however there are no medical treatment options currently available.
Abcentra is developing a pipeline of therapeutic monoclonal antibodies for serious inflammatory diseases where medical treatments are either not available or better options are needed. See our pipeline for more information.